196 related articles for article (PubMed ID: 19064871)
1. Tolerability, adherence, and patient outcomes.
Ross AP
Neurology; 2008 Dec; 71(24 Suppl 3):S21-3. PubMed ID: 19064871
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
Boyko AN
Expert Opin Biol Ther; 2010 Apr; 10(4):653-66. PubMed ID: 20218924
[TBL] [Abstract][Full Text] [Related]
3. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
Girouard N; Théorêt G
Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
[TBL] [Abstract][Full Text] [Related]
4. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
Webb UH
J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
[TBL] [Abstract][Full Text] [Related]
5. Treatment of pediatric multiple sclerosis and variants.
Pohl D; Waubant E; Banwell B; Chabas D; Chitnis T; Weinstock-Guttman B; Tenembaum S;
Neurology; 2007 Apr; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
[TBL] [Abstract][Full Text] [Related]
6. [Ensuring the long-term effectiveness of MS treatment].
Krankenpfl J; 2005; 43(7-10):235. PubMed ID: 16515305
[No Abstract] [Full Text] [Related]
7. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
Lugaresi A
Expert Opin Drug Deliv; 2009 Sep; 6(9):995-1002. PubMed ID: 19637982
[TBL] [Abstract][Full Text] [Related]
8. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis.
Mohr DC; Goodkin DE; Masuoka L; Dick LP; Russo D; Eckhardt J; Boudewyn AC; Bedell L
Mult Scler; 1999 Jun; 5(3):192-7. PubMed ID: 10408720
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Neilley LK; Griffin C; Stiebling B
Mult Scler; 1996 Dec; 2(5):222-6. PubMed ID: 9050360
[TBL] [Abstract][Full Text] [Related]
10. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.
Lugaresi A; Rottoli MR; Patti F
Expert Rev Neurother; 2014 Sep; 14(9):1029-42. PubMed ID: 25109614
[TBL] [Abstract][Full Text] [Related]
11. [Intensifying the care of MS-patients].
Fredrikson S; Hillert J; Link H; Söderström M; Isberg B
Lakartidningen; 1996 Mar; 93(11):1015-20. PubMed ID: 8656807
[No Abstract] [Full Text] [Related]
12. Not every patient with multiple sclerosis should be treated at time of diagnosis.
Pittock SJ; Weinshenker BG; Noseworthy JH; Lucchinetti CF; Keegan M; Wingerchuk DM; Carter J; Shuster E; Rodriguez M
Arch Neurol; 2006 Apr; 63(4):611-4. PubMed ID: 16606780
[No Abstract] [Full Text] [Related]
13. Medication non-adherence--exploring the conceptual mire.
Lehane E; McCarthy G
Int J Nurs Pract; 2009 Feb; 15(1):25-31. PubMed ID: 19187166
[TBL] [Abstract][Full Text] [Related]
14. Taking part in life: enhancing participation in multiple sclerosis.
Yorkston KM; Johnson KL; Klasner ER
Phys Med Rehabil Clin N Am; 2005 May; 16(2):583-94. PubMed ID: 15893688
[TBL] [Abstract][Full Text] [Related]
15. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a.
Mohr DC; Likosky W; Boudewyn AC; Marietta P; Dwyer P; Van der Wende J; Goodkin DE
Mult Scler; 1998 Dec; 4(6):487-9. PubMed ID: 9987757
[TBL] [Abstract][Full Text] [Related]
16. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
17. A patient's perspective of partnership in the treatment of multiple sclerosis: MS regimes--an orchestrated approach.
von Pückler A
J Neurol Sci; 2013 Dec; 335(1-2):1-4. PubMed ID: 24041734
[TBL] [Abstract][Full Text] [Related]
18. [Imparting the diagnosis and educating patients with multiple sclerosis].
Clanet M; Pigois CG
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1153-6. PubMed ID: 11787349
[TBL] [Abstract][Full Text] [Related]
19. A Multiple Sclerosis (MS) Center Injection Training Program.
Pfohl DC
Axone; 1997 Dec; 19(2):29-33. PubMed ID: 9481239
[TBL] [Abstract][Full Text] [Related]
20. What can be learned from open direct comparative trials in multiple sclerosis?
Khan O
J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
